Voyageur Pharmaceuticals Ltd. (TSE:VM) has released an update.
Voyageur Pharmaceuticals Ltd. has made a significant leap in sustainable healthcare with its latest royalty agreement with Rain Cage Carbon Inc., focusing on the development of carbon-neutral pharmaceuticals. The partnership is set to transform healthcare imaging with EDEN™ carbon capture technology and a new MRI drug, promising eco-friendly solutions and innovative targeted drug delivery. Voyageur’s ‘Earth to Bottle’ strategy is driving the creation of an environmentally conscious drug pipeline, including barium, iodinated, and carbon contrast media products.
For further insights into TSE:VM stock, check out TipRanks’ Stock Analysis page.
